Top

Published in:

01-09-2015 | Review

Functional autoantibodies in systemic sclerosis

Authors: Jeannine Günther, Judith Rademacher, Jakob M. van Laar, Elise Siegert, Gabriela Riemekasten

Published in: Seminars in Immunopathology | Issue 5/2015

Abstract

Functional autoantibodies are an emerging field of research that focuses on the effects of these immunoglobulins when they bind to their target molecules. Accumulating information now exists about the molecular targets and precise binding mechanisms of functional autoantibodies as well as about their downstream effects. These data raise the need to distinguish functional autoantibodies from non-functional autoantibodies with regard to their ability to stimulate or to inhibit their target protein via binding. The presence of autoantibodies has been documented in autoimmune disorders decades ago, but meanwhile, more and more autoantibodies have been identified as functional, acting as pathogenic drivers involved in the induction of organ-specific damage in systemic sclerosis as well as in other autoimmune disorders. These findings offer new opportunities for the development of novel therapeutic strategies.

Mehra S, Walker J, Patterson K, Fritzler MJ (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12(3):340–354. doi:10.1016/j.autrev.2012.05.011 PubMedCrossRef

Klein-Weigel P, Opitz C, Riemekasten G (2011) Systemic sclerosis—a systematic overview: part 1—disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. VASA Z Gefasskrankheiten 40(1):6–19. doi:10.1024/0301-1526/a000065 CrossRef

Gleicher N, Barad D, Weghofer A (2007) Functional autoantibodies, a new paradigm in autoimmunity? Autoimmun Rev 7(1):42–45. doi:10.1016/j.autrev.2007.06.001 PubMedCrossRef

Smilek DE, St Clair EW (2015) Solving the puzzle of autoimmunity: critical questions. F1000prime reports 7:17. doi:10.12703/P7-17

Perricone C, Agmon-Levin N, Ceccarelli F, Valesini G, Anaya JM, Shoenfeld Y (2013) Genetics and autoantibodies. Immunol Res 56(2–3):206–219. doi:10.1007/s12026-013-8396-9 PubMedCrossRef

Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B (2002) Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 109(12):1625–1633. doi:10.1172/JCI14873 PubMedCentralPubMedCrossRef

Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A (2008) Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 8(2):116–120. doi:10.1016/j.autrev.2008.07.005 PubMedCrossRef

Ercolini AM, Miller SD (2009) The role of infections in autoimmune disease. Clin Exp Immunol 155(1):1–15. doi:10.1111/j.1365-2249.2008.03834.x PubMedCentralPubMedCrossRef

Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity—friends or foes? Trends Immunol 30(8):409–414. doi:10.1016/j.it.2009.05.005 PubMedCrossRef

10.

Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, Shoenfeld Y (2013) Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev 12(7):726–740. doi:10.1016/j.autrev.2012.12.005 PubMedCrossRef

11.

Pollard KM (2015) Environment, autoantibodies, and autoimmunity. Front Immunol 6:60. doi:10.3389/fimmu.2015.00060 PubMedCentralPubMedCrossRef

12.

Stepan H, Wallukat G, Schultheiss HP, Faber R, Walther T (2007) Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor? J Reprod Immunol 73(2):130–134. doi:10.1016/j.jri.2006.08.084 PubMedCrossRef

13.

van Venrooij WJ, Zendman AJ, Pruijn GJ (2006) Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 6(1):37–41. doi:10.1016/j.autrev.2006.03.008 PubMedCrossRef

14.

Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349(16):1526–1533. doi:10.1056/NEJMoa021933 PubMedCrossRef

15.

Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, Roussin A, Earnshaw W, Rothfield NF (1991) Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud’s disease. A prospective study. Arthritis Rheum 34(1):68–77PubMedCrossRef

16.

Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35–42. doi:10.1016/j.semarthrit.2005.03.005 PubMedCrossRef

17.

Senecal JL, Henault J, Raymond Y (2005) The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol 32(9):1643–1649PubMed

18.

Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 66(6):754–763. doi:10.1136/ard.2006.062901 PubMedCentralPubMedCrossRef

19.

Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, Muller-Ladner U, Co-authors E (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71(8):1355–1360. doi:10.1136/annrheumdis-2011-200742 PubMedCrossRef

20.

Henault J, Robitaille G, Senecal JL, Raymond Y (2006) DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54(3):963–973. doi:10.1002/art.21646 PubMedCrossRef

21.

Arcand J, Robitaille G, Koenig M, Senecal JL, Raymond Y (2012) The autoantigen DNA topoisomerase I interacts with chemokine receptor 7 and exerts cytokine-like effects on dermal fibroblasts. Arthritis Rheum 64(3):826–834. doi:10.1002/art.33377 PubMedCrossRef

22.

Hamaguchi Y, Kodera M, Matsushita T, Hasegawa M, Inaba Y, Usuda T, Kuwana M, Takehara K, Fujimoto M (2015) Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase iii autoantibodies. Arthritis Rheumatol 67(4):1045–1052. doi:10.1002/art.38994 PubMedCrossRef

23.

Senecal JL, Ichiki S, Girard D, Raymond Y (1993) Autoantibodies to nuclear lamins and to intermediate filament proteins: natural, pathologic or pathogenic? J Rheumatol 20(2):211–219PubMed

24.

Naparstek Y, Plotz PH (1993) The role of autoantibodies in autoimmune disease. Annu Rev Immunol 11:79–104. doi:10.1146/annurev.iy.11.040193.000455 PubMedCrossRef

25.

Wallukat G, Schimke I (2014) Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin Immunopathol 36(3):351–363. doi:10.1007/s00281-014-0425-9 PubMedCrossRef

26.

Roitt IM, Doniach D (1957) Auto-immunization in thyroid diseases. Proc R Soc Med 50(11):958–961PubMed

27.

Smart GA (1959) Discussion on the importance of auto-antibody disease in clinical medicine; introduction: renal and thyroid diseases. Proc R Soc Med 52(6):437–440PubMed

28.

Islam MN, Briones-Urbina R, Bako G, Farid NR (1983) Both TSH and thyroid-stimulating antibody of Graves’ disease bind to an Mr 197,000 holoreceptor. Endocrinology 113(1):436–438. doi:10.1210/endo-113-1-436 PubMedCrossRef

29.

de Bruin TW, van der Heide D (1984) Anti-TSH receptor antibodies in Graves’ disease modulate the kinetic behaviour of autologous thyroid TSH receptors. Evidence of the IgG-induced cross-linkage of autologous TSH receptors. Acta Endocrinol (Copenh) 105(3):330–340

30.

Huber GK, Safirstein R, Neufeld D, Davies TF (1991) Thyrotropin receptor autoantibodies induce human thyroid cell growth and c-fos activation. J Clin Endocrinol Metab 72(5):1142–1147. doi:10.1210/jcem-72-5-1142 PubMedCrossRef

31.

Luft FC (2013) Activating autoantibodies and cardiovascular disease. Physiology 28(4):254–261. doi:10.1152/physiol.00014.2013 PubMedCrossRef

32.

McLachlan SM, Rapoport B (2013) Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid Off J Am Thyroid Assoc 23(1):14–24. doi:10.1089/thy.2012.0374 CrossRef

33.

Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M (1996) A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271(27):16384–16392PubMedCrossRef

34.

Hoebeke J (2001) Molecular mechanisms of anti-G-protein-coupled receptor autoantibodies. Autoimmunity 34(3):161–164PubMedCrossRef

35.

Limas CJ, Goldenberg IF, Limas C (1990) Influence of anti-beta-receptor antibodies on cardiac adenylate cyclase in patients with idiopathic dilated cardiomyopathy. Am Heart J 119(6):1322–1328PubMedCrossRef

36.

Staudt A, Eichler P, Trimpert C, Felix SB, Greinacher A (2007) Fc(gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. J Am Coll Cardiol 49(16):1684–1692. doi:10.1016/j.jacc.2006.11.051 PubMedCrossRef

37.

Pierce KL, Premont RT, Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3(9):639–650. doi:10.1038/nrm908 PubMedCrossRef

38.

Podlowski S, Luther HP, Morwinski R, Muller J, Wallukat G (1998) Agonistic anti-beta1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the beta1-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation 98(22):2470–2476PubMedCrossRef

39.

Dragun D, Distler JH, Riemekasten G, Distler O (2009) Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum 60(4):907–911. doi:10.1002/art.24364 PubMedCrossRef

40.

Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354(25):2667–2676. doi:10.1056/NEJMoa052955 PubMedCrossRef

41.

Gabrielli A, Svegliati S, Moroncini G, Avvedimento EV (2007) Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 19(6):640–645. doi:10.1016/j.coi.2007.11.004 PubMedCrossRef

42.

Classen JF, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikstrom G, Rorsman C, Lenglez S, Franck-Larsson K, Tomasi JP, Kampe O, Vanthuyne M, Houssiau FA, Demoulin JB (2009) Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 60(4):1137–1144. doi:10.1002/art.24381 PubMedCrossRef

43.

Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L, Wigley F, Kussie P (2009) Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 60(4):1145–1151. doi:10.1002/art.24365 PubMedCrossRef

44.

Kurasawa K, Arai S, Owada T, Maezawa R, Kumano K, Fukuda T (2010) Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus. Mod Rheumatol Japan Rheum Assoc 20(5):458–465. doi:10.1007/s10165-010-0310-x CrossRef

45.

Moroncini G, Grieco A, Nacci G, Paolini C, Tonnini C, Pozniak KN, Cuccioloni M, Mozzicafreddo M, Svegliati S, Angeletti M, Kazlauskas A, Avvedimento EV, Funaro A, Gabrielli A (2015) Epitope specificity determines pathogenicity and detectability of anti-PDGFRalpha autoantibodies in systemic sclerosis. Arthritis Rheumatol. doi:10.1002/art.39125

46.

Yang Y, Yuzawa S, Schlessinger J (2008) Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Proc Natl Acad Sci U S A 105(22):7681–7686. doi:10.1073/pnas.0802896105 PubMedCentralPubMedCrossRef

47.

Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117–1134. doi:10.1016/j.cell.2010.06.011 PubMedCentralPubMedCrossRef

48.

Ortona E, Pierdominici M, Berstein L (2014) Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer. J Steroid Biochem Mol Biol 144(Pt B):260–267. doi:10.1016/j.jsbmb.2014.07.004 PubMedCrossRef

49.

Grimaldi CM, Hicks R, Diamond B (2005) B cell selection and susceptibility to autoimmunity. J Immunol 174(4):1775–1781PubMedCrossRef

50.

Ueda K, Karas RH (2013) Emerging evidence of the importance of rapid, non-nuclear estrogen receptor signaling in the cardiovascular system. Steroids 78(6):589–596. doi:10.1016/j.steroids.2012.12.006 PubMedCrossRef

51.

Kovats S (2015) Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol 294(2):63–69. doi:10.1016/j.cellimm.2015.01.018 PubMedCrossRef

52.

Pierdominici M, Maselli A, Colasanti T, Giammarioli AM, Delunardo F, Vacirca D, Sanchez M, Giovannetti A, Malorni W, Ortona E (2010) Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol Lett 132(1–2):79–85. doi:10.1016/j.imlet.2010.06.003 PubMedCrossRef

53.

Mudarris A, Peck EJ Jr (1987) Human anti-estrogen receptor antibodies: assay, characterization, and age- and sex-related differences. J Clin Endocrinol Metab 64(2):246–254. doi:10.1210/jcem-64-2-246 PubMedCrossRef

54.

Colasanti T, Maselli A, Conti F, Sanchez M, Alessandri C, Barbati C, Vacirca D, Tinari A, Chiarotti F, Giovannetti A, Franconi F, Valesini G, Malorni W, Pierdominici M, Ortona E (2012) Autoantibodies to estrogen receptor alpha interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus. Arthritis Rheum 64(3):778–787. doi:10.1002/art.33400 PubMedCrossRef

55.

Giovannetti A, Maselli A, Colasanti T, Rosato E, Salsano F, Pisarri S, Mezzaroma I, Malorni W, Ortona E, Pierdominici M (2013) Autoantibodies to estrogen receptor alpha in systemic sclerosis (SSc) as pathogenetic determinants and markers of progression. PloS One 8(9):e74332. doi:10.1371/journal.pone.0074332 PubMedCentralPubMedCrossRef

56.

Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC (1999) Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 103(7):945–952. doi:10.1172/JCI4106 PubMedCentralPubMedCrossRef

57.

Xia Y, Kellems RE (2009) Is preeclampsia an autoimmune disease? Clin Immunol 133(1):1–12. doi:10.1016/j.clim.2009.05.004 PubMedCentralPubMedCrossRef

58.

Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjogren KG, Hjalmarson A, Muller-Esterl W, Hoebeke J (2000) Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 18(7):945–953PubMedCrossRef

59.

Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schonemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G (2005) Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352(6):558–569. doi:10.1056/NEJMoa035717 PubMedCrossRef

60.

Riemekasten G, Philippe A, Nather M, Slowinski T, Muller DN, Heidecke H, Matucci-Cerinic M, Czirjak L, Lukitsch I, Becker M, Kill A, van Laar JM, Catar R, Luft FC, Burmester GR, Hegner B, Dragun D (2011) Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 70(3):530–536. doi:10.1136/ard.2010.135772 PubMedCrossRef

61.

Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, Witzenrath M, Kuhl AA, Heidecke H, Ghofrani HA, Tiede H, Schermuly RT, Nickel N, Hoeper MM, Lukitsch I, Gollasch M, Kuebler WM, Bock S, Burmester GR, Dragun D, Riemekasten G (2014) Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 190(7):808–817. doi:10.1164/rccm.201403-0442OC PubMedCrossRef

62.

Gunther J, Kill A, Becker MO, Heidecke H, Rademacher J, Siegert E, Radic M, Burmester GR, Dragun D, Riemekasten G (2014) Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 16(2):R65. doi:10.1186/ar4503 PubMedCentralPubMedCrossRef

63.

Kill A, Tabeling C, Undeutsch R, Kuhl AA, Gunther J, Radic M, Becker MO, Heidecke H, Worm M, Witzenrath M, Burmester GR, Dragun D, Riemekasten G (2014) Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 16(1):R29. doi:10.1186/ar4457 PubMedCentralPubMedCrossRef

64.

Trojanowska M (2009) Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 21(6):623–629. doi:10.1097/BOR.0b013e32833038ce PubMedCentralPubMedCrossRef

65.

LeRoy EC (1974) Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54(4):880–889. doi:10.1172/JCI107827 PubMedCentralPubMedCrossRef

66.

Jimenez SA, Feldman G, Bashey RI, Bienkowski R, Rosenbloom J (1986) Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis fibroblasts. Biochem J 237(3):837–843PubMedCentralPubMedCrossRef

67.

Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Muller-Quernheim J, Zissel G (2006) A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 173(7):781–792. doi:10.1164/rccm.200509-1518OC PubMedCrossRef

68.

Pochetuhen K, Luzina IG, Lockatell V, Choi J, Todd NW, Atamas SP (2007) Complex regulation of pulmonary inflammation and fibrosis by CCL18. Am J Pathol 171(2):428–437. doi:10.2353/ajpath.2007.061167 PubMedCentralPubMedCrossRef

69.

Schupp J, Becker M, Gunther J, Muller-Quernheim J, Riemekasten G, Prasse A (2014) Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur Respir J 43(5):1530–1532. doi:10.1183/09031936.00131713 PubMedCrossRef

70.

Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG et al (1993) In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiol J Immunopathol Mol Cell Biol 61(5–6):239–246CrossRef

71.

Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E (1998) Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjogren’s syndrome. Invest Ophthalmol Vis Sci 39(1):151–156PubMed

72.

Patel R, Shahane A (2014) The epidemiology of Sjogren’s syndrome. Clin Epidemiol 6:247–255. doi:10.2147/CLEP.S47399 PubMedCentralPubMed

73.

Goldblatt F, Gordon TP, Waterman SA (2002) Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 123(4):1144–1150PubMedCrossRef

74.

Singh J, Mehendiratta V, Del Galdo F, Jimenez SA, Cohen S, DiMarino AJ, Rattan S (2009) Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 297(6):G1206–G1213. doi:10.1152/ajpgi.00286.2009 PubMedCentralPubMedCrossRef

75.

Singh J, Cohen S, Mehendiratta V, Mendoza F, Jimenez SA, Dimarino AJ, Rattan S (2012) Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function. Gastroenterology 143(5):1308–1318. doi:10.1053/j.gastro.2012.07.109 PubMedCentralPubMedCrossRef

76.

Cavill D, Waterman SA, Gordon TP (2004) Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren’s syndrome. Scand J Immunol 59(3):261–266. doi:10.1111/j.0300-9475.2004.01395.x PubMedCrossRef

77.

Preuss B, Tunaru S, Henes J, Offermanns S, Klein R (2014) A novel luminescence-based method for the detection of functionally active antibodies to muscarinic acetylcholine receptors of the M3 type (mAchR3) in patients’ sera. Clin Exp Immunol 177(1):179–189. doi:10.1111/cei.12324 PubMedCentralPubMedCrossRef

78.

Lukitsch I, Kehr J, Chaykovska L, Wallukat G, Nieminen-Kelha M, Batuman V, Dragun D, Gollasch M (2012) Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 94(1):8–13. doi:10.1097/TP.0b013e3182529bb7 PubMedCrossRef

79.

Carvalho D, Savage CO, Black CM, Pearson JD (1996) IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 97(1):111–119. doi:10.1172/JCI118377 PubMedCentralPubMedCrossRef

80.

Arends SJ, Damoiseaux JG, Duijvestijn AM, Debrus-Palmans L, Vroomen M, Boomars KA, Brunner-La Rocca HP, Reutelingsperger CP, Cohen Tervaert JW, van Paassen P (2013) Immunoglobulin G anti-endothelial cell antibodies: inducers of endothelial cell apoptosis in pulmonary arterial hypertension? Clin Exp Immunol 174(3):433–440. doi:10.1111/cei.12166 PubMedCentralPubMedCrossRef

81.

Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R, Puccetti A (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6(10):1183–1186. doi:10.1038/80533 PubMedCrossRef

82.

Tachibana I, Bodorova J, Berditchevski F, Zutter MM, Hemler ME (1997) NAG-2, a novel transmembrane-4 superfamily (TM4SF) protein that complexes with integrins and other TM4SF proteins. J Biol Chem 272(46):29181–29189PubMedCrossRef

83.

Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, Tamassia N, Beri R, Corrocher R, Puccetti A (2006) Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 3(1):e2. doi:10.1371/journal.pmed.0030002 PubMedCentralPubMedCrossRef

84.

Wolf SI, Howat S, Abraham DJ, Pearson JD, Lawson C (2013) Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades. Vasc Pharmacol 59(1–2):19–26. doi:10.1016/j.vph.2013.05.002 CrossRef

85.

Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, Facchini A, Del Papa N, Borghi MO, Dayer JM, Meroni PL (2002) Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 46(6):1602–1613. doi:10.1002/art.10361 PubMedCrossRef

86.

Tamby MC, Humbert M, Guilpain P, Servettaz A, Dupin N, Christner JJ, Simonneau G, Fermanian J, Weill B, Guillevin L, Mouthon L (2006) Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 28(4):799–807. doi:10.1183/09031936.06.00152705 PubMedCrossRef

87.

Terrier B, Tamby MC, Camoin L, Guilpain P, Broussard C, Bussone G, Yaici A, Hotellier F, Simonneau G, Guillevin L, Humbert M, Mouthon L (2008) Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 177(10):1128–1134. doi:10.1164/rccm.200707-1015OC PubMedCrossRef

88.

Terrier B, Tamby MC, Camoin L, Guilpain P, Berezne A, Tamas N, Broussard C, Hotellier F, Humbert M, Simonneau G, Guillevin L, Mouthon L (2010) Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis 69(2):428–433. doi:10.1136/ard.2008.104299 PubMedCrossRef

89.

Jimenez SA, Hitraya E, Varga J (1996) Pathogenesis of scleroderma. Collagen. Rheum Dis Clin N Am 22(4):647–674CrossRef

90.

Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Investig Dermatol 120(4):542–547. doi:10.1046/j.1523-1747.2003.12097.x PubMedCrossRef

91.

Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, Sato S (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138(2):357–363. doi:10.1111/j.1365-2249.2004.02615.x PubMedCentralPubMedCrossRef

92.

Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, Ouyang J, Kozak T, Moore J, Kotter I, Chesnel V, Marmont A, Gratwohl A, Saccardi R (2010) Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 95(2):284–292. doi:10.3324/haematol.2009.013458 PubMedCentralPubMedCrossRef

93.

van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kotter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quere I, Rich E, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socie G, Gratwohl A, Tyndall A, Group EESS (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490–2498. doi:10.1001/jama.2014.6368 PubMedCrossRef

94.

Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6(10):741–750. doi:10.1038/nri1886 PubMedCrossRef

95.

Hoyer BF, Manz RA, Radbruch A, Hiepe F (2005) Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 1050:124–133. doi:10.1196/annals.1313.014 PubMedCrossRef

96.

Illei GG, Cervera R, Burt RK, Doria A, Hiepe F, Jayne D, Pavletic S, Martin T, Marmont A, Saccardi R, Voskuyl AE, Farge D (2011) Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis 70(12):2071–2074. doi:10.1136/ard.2010.148049 PubMedCentralPubMedCrossRef

97.

Humbert M, Cabane J (2003) Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology 42(1):191–193PubMedCrossRef

98.

Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50(12):3985–3993. doi:10.1002/art.20676 PubMedCrossRef

99.

Tillon J, Herve F, Chevallier D, Muir JF, Levesque H, Marie I (2006) Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy. Br J Dermatol 154(5):1000–1002. doi:10.1111/j.1365-2133.2006.07194.x PubMedCrossRef

100.

Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, Stefanadis C, Mavrikakis M (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56(6):1985–1993. doi:10.1002/art.22634 PubMedCrossRef

101.

Ambach A, Seo W, Bonnekoh B, Gollnick H (2009) Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil. J Dtsch Dermatol Ges J Ger Soc Dermatol: JDDG 7(10):888–891. doi:10.1111/j.1610-0387.2009.07057.x

102.

Gholam P, Sehr T, Enk A, Hartmann M (2009) Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan). Dermatology 219(2):171–173. doi:10.1159/000228318 PubMedCrossRef

103.

Nishibu A, Sakai E, Oyama N, Yamamoto T (2012) Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis. Aust J Dermatol 53(2):e32–e33. doi:10.1111/j.1440-0960.2010.00719.x CrossRef

104.

Cutolo M, Ruaro B, Pizzorni C, Ravera F, Smith V, Zampogna G, Paolino S, Seriolo B, Cimmino M, Sulli A (2014) Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol 41(5):881–886. doi:10.3899/jrheum.131284 PubMedCrossRef

105.

Chung L, Ball K, Yaqub A, Lingala B, Fiorentino D (2014) Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study. J Am Acad Dermatol 71(2):400–401. doi:10.1016/j.jaad.2014.04.028 PubMedCentralPubMedCrossRef

106.

Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42(12):2646–2655. doi:10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T PubMedCrossRef

107.

McQueen FM, Solanki K (2015) Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology. doi:10.1093/rheumatology/keu463 PubMed

108.

Hohenstein B, Bornstein SR, Aringer M (2013) Immunoadsorption for connective tissue disease. Atheroscler Suppl 14(1):185–189. doi:10.1016/j.atherosclerosissup.2012.10.034 PubMedCrossRef

109.

Hessel FP, Wegner C, Muller J, Glaveris C, Wasem J (2004) Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Eur J Health Econ: HEPAC: Health Econ Prev Care 5(1):58–63. doi:10.1007/s10198-003-0202-5 CrossRef

110.

Dandel M, Wallukat G, Englert A, Hetzer R (2013) Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atheroscler Suppl 14(1):203–211. doi:10.1016/j.atherosclerosissup.2012.10.029 PubMedCrossRef

111.

Haberland A, Wallukat G, Schimke I (2011) Aptamer binding and neutralization of beta1-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment. Trends Cardiovasc Med 21(6):177–182. doi:10.1016/j.tcm.2012.05.006 PubMedCrossRef

112.

Haberland A, Wallukat G, Schimke I (2013) The patent situation concerning the treatment of diseases associated with autoantibodies directed against G-protein-coupled receptors. Pharm Patent Anal 2(2):231–248. doi:10.4155/ppa.12.88 CrossRef

Title: Functional autoantibodies in systemic sclerosis
Authors: Jeannine Günther
Judith Rademacher
Jakob M. van Laar
Elise Siegert
Gabriela Riemekasten
Publication date: 01-09-2015
Publisher: Springer Berlin Heidelberg
Published in: Seminars in Immunopathology / Issue 5/2015
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-015-0513-5

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment

Fibrogenesis, novel lessons from animal models

Vasculopathy in scleroderma

The role of the acquired immune response in systemic sclerosis

Matrix remodeling in systemic sclerosis

Genetics of systemic sclerosis

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage